Technical Analysis for IMU - Imugene Limited
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 0.037 | -7.50% | -0.003 |
Earnings due: Nov 29
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| Expansion Breakdown | Bearish Swing Setup | 0.00% | |
| Volume Surge | Other | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | -7.50% | |
| Expansion Breakdown | Bearish Swing Setup | -7.50% |
| Alert | Time |
|---|---|
| Down 10% | about 11 hours ago |
| Down 1 ATR | about 12 hours ago |
| Down 5% | about 12 hours ago |
| Fell Below Previous Day's Low | about 13 hours ago |
| 3x Volume Pace | about 13 hours ago |
Get this analysis on your stocks daily!
Imugene Limited Description
Imugene Limited is an immuno-oncology focused biopharmaceutical company. The Company is engaged in the research and development of human epidermal growth factor receptor 2 positive (HER2 +ve), and gastric and breast cancer vaccines. The Company is also engaged in the research, development and commercialization of health technologies. HER-Vaxx is a cancer immunotherapy designed to treat tumors that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. HER-Vaxx has completed a Phase I clinical trial with over 10 HER-2 positive patients with metastatic breast cancer. It was shown in pre-clinical studies and in one Phase 1 study to stimulate a potent polyclonal antibody response to HER-2/neu. HER-Vaxx has stimulated the production of HER-2 antibodies in early-stage cancer patients enrolled in the initial clinical trial. The Company is also developing mimotope-based immunotherapies against validated and oncology targets.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Health Gas Medicine Pharmaceutical Cancer Clinical Trial Biopharmaceutical Cancers Therapy Breast Cancer Tumor Oncology Tumors Biotechnology Companies Cancer Immunotherapy Antibodies Cancer Treatments Health Technologies Her2/Neu Metastatic Breast Cancer Pancreatic Cancers
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 0.13 |
| 52 Week Low | 0.035 |
| Average Volume | 19,022,942 |
| 200-Day Moving Average | 0.069 |
| 50-Day Moving Average | 0.048 |
| 20-Day Moving Average | 0.045 |
| 10-Day Moving Average | 0.043 |
| Average True Range | 0.003 |
| RSI (14) | 36.31 |
| ADX | 19.22 |
| +DI | 17.027 |
| -DI | 38.919 |
| Chandelier Exit (Long, 3 ATRs) | 0.044 |
| Chandelier Exit (Short, 3 ATRs) | 0.043 |
| Upper Bollinger Bands | 0.051 |
| Lower Bollinger Band | 0.039 |
| Percent B (%b) | -0.12 |
| BandWidth | 27.740 |
| MACD Line | -0.002 |
| MACD Signal Line | -0.002 |
| MACD Histogram | -0.0007 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.045 | ||||
| Resistance 3 (R3) | 0.045 | 0.042 | 0.043 | ||
| Resistance 2 (R2) | 0.042 | 0.040 | 0.042 | 0.043 | |
| Resistance 1 (R1) | 0.040 | 0.039 | 0.039 | 0.040 | 0.042 |
| Pivot Point | 0.037 | 0.037 | 0.037 | 0.037 | 0.037 |
| Support 1 (S1) | 0.035 | 0.035 | 0.034 | 0.035 | 0.032 |
| Support 2 (S2) | 0.032 | 0.034 | 0.032 | 0.031 | |
| Support 3 (S3) | 0.030 | 0.032 | 0.031 | ||
| Support 4 (S4) | 0.030 |
